Bionano Genomics Reports Q4 and Full-Year 2025 Results: Key Investor Insights

Executive Summary & Key Points

Bionano Genomics, Inc. (Nasdaq: BNGO) has released its financial results for the fourth quarter and full year ended December 31, 2025, and provided revenue guidance for 2026. The results and outlook contain several important developments that shareholders and potential investors should note, as they may affect the company’s share price.

Highlights from Management

• CEO Erik Holmlin emphasized ongoing momentum in the business, driven by the adoption of Bionano’s Optical Genome Mapping (OGM) technology and VIA™ software. Routine users of OGM and VIA™ remain the foundation for revenue and gross margins.
• The company highlighted increasing engagement from the global OGM community, with expanded clinical research evidence and rising utilization rates.
• A significant price-sensitive event: The Centers for Medicare & Medicaid Services (CMS) has increased the 2026 Clinical Lab Fee Schedule payment determination for the Category I CPT code for OGM use in hematologic malignancies by 47%. This is a strong signal of broader clinical acceptance and could impact future revenues and market adoption.

Fourth Quarter 2025 Financial Results

• Revenue: Q4 2025 total revenue was \$8.0 million, a decrease of 3% from \$8.2 million in Q4 2024.
• Consumables and software revenues decreased 1%.
• Instrument revenue was \$2.7 million, slightly down from \$2.8 million in Q4 2024.
• Sold 7,554 nanochannel array flowcells, down 6% from 8,058 the prior year.
• Installed base increased: 9 new OGM systems installed, 6 brought back, ending the quarter with 387 systems (+4% from 371 last year).
• Gross margin: Q4 gross margin was 43%, up from 42% the previous year; non-GAAP gross margin also 43%.
• Operating expenses: Reduced by 22% to \$11.9 million; non-GAAP operating expense down 9% to \$9.7 million.

Full-Year 2025 Financial Results

• Revenue: FY2025 total revenue was \$28.5 million, down 7% from \$30.8 million in 2024.
• Consumables and software revenues increased 7%.
• Instrument revenue fell to \$6.4 million (from \$8.0 million in 2024).
• Clinical services revenue (\$1.7 million in 2024) discontinued.
• Sold 30,171 flowcells (vs. 30,307 in 2024).
• Installed 32 new OGM systems and brought 16 back, ending with 387 systems.
• Gross margin: FY2025 gross margin was 46% (up sharply from 1% in 2024); non-GAAP gross margin 47% (up from 35%).
• Operating expenses: Reduced by 55% to \$46.5 million; non-GAAP operating expense down 47% to \$36.6 million.
• Cash, cash equivalents, available-for-sale securities, and restricted short-term investments totaled \$29.6 million at year-end.

Recent Business Highlights

• CMS Fee Schedule Increase: The 47% increase in reimbursement for OGM in hematologic malignancies is a major development, potentially accelerating clinical adoption and revenue.
• Bionano Symposium 2026: Record attendance, nearly 40 presentations, and growing momentum in OGM adoption for diverse applications.
• International Expansion: Ongoing efforts to standardize OGM workflows across global labs.
• Professional Society Support: Initiatives with ACMG, AMP, and CAP to develop technical standards and points-to-consider documents, broadening acceptance of OGM.
• Research Publications: Over 136 peer-reviewed publications in Q4 2025, plus new studies showcased at AMP 2025 and ASHG 2025.
• New Applications: OGM used for detecting gene editing-induced genomic alterations.

2026 Revenue Outlook

• Q1 2026 Guidance: Revenue expected between \$6.5 – \$6.7 million.
• Full-Year 2026 Guidance: Revenue expected between \$30 – \$33 million (implying flat to slight growth).

Balance Sheet Snapshot (as of December 31, 2025)

• Total assets: \$73.6 million
• Total liabilities: \$29.2 million
• Total stockholders’ equity: \$44.4 million
• Cash and equivalents: \$2.99 million
• Investments: \$16.28 million
• Restricted cash and investments: \$10.27 million

Profit & Loss Statement Highlights

• Net loss (Q4 2025): \$7.93 million
• Net loss (FY2025): \$26.4 million (vs. \$112.0 million in 2024)
• Loss from operations (FY2025): \$33.3 million (vs. \$104.0 million in 2024)

Non-GAAP Financial Measures

• Bionano reports non-GAAP gross margin and operating expenses, which exclude stock-based compensation, restructuring expenses, impairment and disposal of reagent rentals and inventory, amortization of intangibles, changes in fair value of contingent consideration, transaction-related expenses, and loss on disposals.
• Non-GAAP gross margin and operating expenses are used to better analyze performance and trends, though investors should be aware these measures are not standardized and may differ from those used by other companies.

Forward-Looking Statements and Risk Factors

• Bionano cautions investors that forward-looking statements are subject to risks and uncertainties, including: ability to improve margins, extend cash runway, reach profitability, and secure additional financing; execution of strategy; impact of CMS reimbursement changes; continued adoption and research on OGM; competitive landscape; regulatory developments; integration of acquisitions; geopolitical and macroeconomic risks; and more.
• Going concern risk: The company must manage costs and obtain significant additional financing to fund strategic plans and commercialization efforts within the next 12 months.

Contacts

Company Contact: Erik Holmlin, CEO, Bionano Genomics, Inc.
Investor Relations: Webb Campbell, Gilmartin Group

Conclusion: Price-Sensitive Takeaways

• The 47% CMS reimbursement increase for OGM in hematologic malignancies is a major price-sensitive event, likely to accelerate clinical adoption and potentially boost future revenues.
• The company has significantly reduced its operating expenses and net losses, suggesting improved financial discipline.
• However, total revenues declined year-over-year, and the company faces ongoing challenges with achieving profitability and maintaining cash runway.
• Flat to modest revenue guidance for 2026 may temper investor expectations for near-term growth.
• Clinical adoption, reimbursement developments, and execution of cost controls will be key factors to monitor for share price movement.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties as outlined in Bionano’s SEC filings and may not materialize as expected. Investors should conduct their own due diligence before making any investment decisions.

View Bionano Genomics, Inc. Historical chart here